What are the definition, causes, evaluation, and management of hyperuricemia?

Hyperuricemia: Definition, Causes, Evaluation, and Management

Definition

Hyperuricemia is defined as serum uric acid (SUA) levels >7 mg/dL (420 μmol/L) in men and postmenopausal women, though the threshold at which treatment should be considered is >6 mg/dL (360 μmol/L), as this represents the saturation point for monosodium urate crystal formation and the lifelong risk threshold for gout development 1. This 6 mg/dL cutoff aligns with the minimum target for urate-lowering therapy, facilitating patient adherence to treatment goals.

Causes and Classification

Hyperuricemia results from either:

Primary Hyperuricemia (98-99% of cases)

• Impaired renal excretion of uric acid (most common mechanism) 2, 3
• Uric acid overproduction (rare)
• Mixed type (both mechanisms)

Secondary Hyperuricemia

• Dietary factors: Excessive purine-rich food consumption, alcohol intake
• Medications: Diuretics, low-dose aspirin
• Metabolic conditions: Obesity, insulin resistance, metabolic syndrome
• Renal disease: Chronic kidney disease
• Genetic disorders:
  • HPRT gene deficiency (Lesch-Nyhan syndrome)
  • Uromodulin gene abnormality (familial juvenile hyperuricemic nephropathy)
  • Glucose-6-phosphatase deficiency
• Hematologic malignancies: Tumor lysis syndrome from chemotherapy 2

The pathophysiology involves inflammation, oxidative stress, endothelial dysfunction, and activation of the renin-angiotensin-aldosterone system 4.

Clinical Evaluation

Initial Assessment

Evaluate every patient for:

• Disease burden: Frequency of gout flares, presence of tophi on physical examination, chronic arthropathy
• Comorbidities: Chronic kidney disease (calculate creatinine clearance), hypertension, cardiovascular disease, heart failure, diabetes, metabolic syndrome
• Secondary causes: Review all medications (especially diuretics), assess alcohol consumption, dietary habits
• Renal function: Essential for medication dosing decisions
• Urinary uric acid excretion: Measure 24-hour urinary uric acid before initiating uricosuric therapy to classify as overproducer vs. underexcretor 5

Classification by Pathophysiology

Determine the type:

• Overproduction type: Elevated urinary uric acid (>800 mg/24 hours on regular diet)
• Underexcretion type: Low urinary uric acid (<600 mg/24 hours)
• Mixed type: Features of both

Risk Stratification

• HLA-B*5801 testing: Consider in high-risk populations before starting allopurinol (Koreans with stage 3+ CKD; Han Chinese and Thai patients regardless of renal function) 5
• History of urolithiasis: Contraindicates first-line uricosuric monotherapy 5

Management

Non-Pharmacologic Management

All patients require lifestyle modifications:

• Dietary changes: Limit purine-rich foods (organ meats, certain seafood), reduce alcohol (especially beer), limit fructose-containing beverages
• Weight management: Gradual weight loss if obese (avoid rapid weight loss which can precipitate flares)
• Hydration: Increase fluid intake, especially if using uricosuric therapy
• Address comorbidities: Optimize management of hypertension, diabetes, dyslipidemia (these take priority over gout-specific dietary restrictions) 5

Pharmacologic Urate-Lowering Therapy (ULT)

Treatment Target

Target SUA <6 mg/dL (360 μmol/L) for all gout patients; consider <5 mg/dL (300 μmol/L) for severe disease with tophi or chronic tophaceous gout 5. The 2024 Chinese guidelines suggest maintaining levels between 180-300 μmol/L (3-5 mg/dL) for chronic gout 6.

First-Line Options

Xanthine Oxidase Inhibitors (XOIs):

Allopurinol 5:

• Start at ≤100 mg/day (50 mg/day if stage 4+ CKD)
• Titrate upward every 2-5 weeks to achieve target SUA
• Can exceed 300 mg/day even with renal impairment, with proper monitoring for toxicity (pruritus, rash, elevated transaminases)
• Monitor for hypersensitivity reactions

Febuxostat:

• Alternative first-line XOI, can be substituted for allopurinol in cases of intolerance 5
• Do not combine febuxostat with allopurinol (per drug labeling)
• Recent evidence shows conflicting cardiovascular safety data: CARES trial showed increased mortality vs. allopurinol, while FAST trial showed non-inferiority 4
• The 2024 Chinese guidelines recommend febuxostat as first-line for asymptomatic hyperuricemia 6

Uricosuric Therapy:

Probenecid 5:

• First choice among uricosurics for monotherapy
• Not recommended if creatinine clearance <50 mL/min
• Contraindications: History of urolithiasis, elevated urinary uric acid indicating overproduction
• Requires monitoring of urinary uric acid throughout treatment
• Consider urine alkalinization with potassium citrate (target pH monitoring) plus increased fluid intake to reduce urolithiasis risk

Alternative uricosurics:

• Fenofibrate and losartan have clinically significant uricosuric effects and can be incorporated into comprehensive ULT strategy 5

Refractory Disease Management

For patients failing initial ULT 5:

1. First step: Titrate current XOI to maximum appropriate dose
2. Second step: Switch XOI (febuxostat ↔ allopurinol) if intolerance or inadequate response despite dose titration
3. Combination therapy: Add uricosuric agent (probenecid, fenofibrate, or losartan) to XOI, or vice versa
4. Pegloticase: Reserved for severe gout with refractory disease or intolerance to conventional ULT
   • Not recommended as first-line therapy
   • Discontinue all oral ULT during pegloticase therapy to avoid masking loss of efficacy and increased infusion reaction risk
   • Appropriate for patients with severe disease burden and tophi

Anti-Inflammatory Prophylaxis

During ULT initiation and titration, provide prophylaxis against gout flares (typically with colchicine or low-dose NSAIDs). The 2024 Chinese guidelines recommend prolonged glucocorticoid tapering combined with colchicine for chronic gout management 6.

Special Populations

Pregnancy/Lactation: Use febuxostat with caution 6

Asymptomatic Hyperuricemia: The decision to treat remains controversial. Recent evidence shows monosodium urate deposits can occur in asymptomatic patients and may precede flares 1. Treatment decisions should weigh cardiovascular and renal risks, though evidence for treating asymptomatic hyperuricemia to prevent these complications remains conflicting 7, 4.

Common Pitfalls

• Allopurinol under-dosing: Many patients remain on 300 mg/day without titration to target SUA
• Starting ULT during acute flare: Initiate after flare resolution with appropriate prophylaxis
• Inadequate prophylaxis: Leads to early flares and treatment discontinuation
• Ignoring renal function: Critical for drug selection and dosing
• Failing to measure urinary uric acid: Before starting uricosuric therapy
• Not monitoring for allopurinol hypersensitivity: Especially in high-risk ethnic groups without HLA-B*5801 testing